Navigation Links
China Medical Technologies Reports Third Fiscal Quarter Financial Results
Date:2/18/2011

1,439Convertible notes issuance costs

-

1,018

154Due from a related party

200,715

118,800

18,000Total current assets

1,380,183

1,663,084

251,982Property, plant and equipment, net

147,355

144,251

21,857Land use rights

6,954

6,906

1,046Goodwill

8,654

8,654

1,311Intangible assets, net

3,128,820

3,042,474

460,981Convertible notes issuance costs

34,782

60,163

9,116Share lending costs

27,905

25,133

3,808Total assets

4,734,653

4,950,665

750,101Liabilities Current liabilitiesTrade accounts payable

43,958

44,477

6,739Accrued liabilities and other payables

173,693

174,978

26,512Convertible notes

-

186,763

28,297Income taxes payable

59,334

63,859

9,676Total current liabilities

276,985

470,077

71,224Convertible notes

2,528,848

2,626,800

398,000Deferred income taxes

78,408

84,936

12,869Total liabilities

2,884,241

3,181,813

482,093Shareholders' equityOrdinary shares US$0.1 par value:   500,000,000 authorized; 322,680,001 issued and   outstanding as of September 30, 2010 and December   31, 2010

258,840

258,840

39,218Additional paid-in capital

830,016

869,439

131,733Treasury stock

(47,108)

(201,362)

(30,509)Accumulated other comprehensive loss

(74,412)

(76,923)

(11,655)Retained earnings

883,076

918,858

139,221Total shareholders' equity

1,850,412

1,768,852

268,008Total liabilities and shareholders' equity

4,734,653

4,950,665

750,101China Medical Technologies, Inc.Unaudited Condensed Consolidated Statements of Income andReconciliat
'/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. China SHESAYS Updates on Progress of Commencing Operations at its New Flagship Hospital
2. ThermoGenesis Reports Second Quarter 2011 Results; Increased Presence in China
3. China-Biotics, Inc. Reports Record Quarterly Net Sales for the Third quarter of Fiscal Year 2011
4. China Medicine Corporation Receives Manufacturing License for rADTZ
5. China SHESAYS Announces Preliminary Unaudited Results for FY 2010; Provides Business Outlook Update for Investors
6. China Medical Technologies to Announce Results for the Third Fiscal Quarter Ended December 31, 2010 on February 18, 2011
7. China Sky One Medical Receives Medical Industry Awards
8. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
9. Reportlinker Adds The Top 10 CMOs in China
10. Shareholder Letter from Chairman of China Sky One Medical
11. Wolters Kluwer Health Enters Joint Venture with China Drug Information Provider Medicom
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... DES MOINES, Iowa , Jan. 23, 2015  The Partnership to ... Iowa health care leaders and a new study ... prescription medications. The PFCD is a nationwide coalition working to educate ... The research released at the Capitol was focused on how the ...
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015 ... with KRS Global Biotechnology, Inc. for the compounding, packaging and ... for shipment in the United States . ... Outsourcing Facility capable of compounding naltrexone tablets in various strengths ...
(Date:1/23/2015)...  iMD Companies, Inc. (ICBU) has repositioned itself as a holding ... a foothold in the hydroponic, hemp and medical marijuana sectors. ... in the sector, and recently partnering with the Chippewa Tribe ... medical marijuana, iMD is committing to bring its vision to ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
(Date:1/22/2015)... EAGAN, Minn. (PRWEB) January 22, 2015 Blue ... discover those Minnesotans who exemplify what it means to “Live ... a chance for people to share their stories about how ... adversity or simply inspired others by living in the moment. ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Amneal Pharmaceuticals is,pleased to announce that it ... USP in strengths of 5mg, 10mg, 25mg and ... an AA-Rated,therapeutically equivalent alternative to Urecholine(R) (a trademark ... breakthrough for Amneal, who is,one of the very ...
... Ill., Nov. 29 Abbott (NYSE:,ABT)announced today that ... Food and Drug Administration (FDA) recommended approval for ... V is a,next-generation drug eluting stent intended for ... The FDA advisory committee voted to recommend the ...
... (NYSE: BSX ) today welcomed the recommendation ... panel to approve with conditions the,PROMUS(TM) / XIENCE(TM) ... V stent systems are identical products, sold respectively,by ... stent,systems would be covered by the same FDA ...
... Nov. 29 As early detection and treatments,improve, ... Autism and,Asperger,s Syndrome are considering higher education., ... of an aging population,with autism, others have turned ... with Autism and Developmental Disabilities (AHEADD), to,enhance their ...
... 2007 Traditionally, clinicians have relied on information ... as the primary means of assessing patients symptoms ... arise if important symptoms go unreported during those ... new study by researchers at Memorial Sloan-Kettering Cancer ...
... Experts Address Smart Solutions to Keep Program,Accessible and Affordable, ... Medical Society hosted a panel discussion with local voters ... Medicare could,leave the program after scheduled pay cuts go ... people in the program to find a doctor. But ...
Cached Medicine News:Health News:FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 2Health News:Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System 3Health News:Autism U: As College Application Deadlines Near, Growing Adult Autism Population Focuses on Higher Education 2Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:AARP Pennsylvania Hosts Panel on Strengthening Medicare 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: